Synthetic regenerative graft developer Medical 21 files for a $25 million IPO
Medical 21, which is developing a synthetic regenerative graft for coronary bypass surgery, filed on Thursday with the SEC to raise up to $25 million in an initial public offering.
Source: https://www.renaissancecapital.com/
First-in-human trial of regenerative coronary bypass graft to commence
Medical 21 has received regulatory approval in Spain under the European Union Medical Device Regulation (EU MDR) to initiate the company’s first-in-human, multicentre clinical trial of the Maverics graft—a novel regenerative small-diameter coronary bypass graft—the MAVERICS coronary revascularization study.
Source: Cardiovascular News
Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain
Regulatory clearance enables launch of the MAVERICS Coronary Revascularization Study, advancing evaluation of the Company's next-generation synthetic small-diameter bypass graft.
Source: Yahoo Finance
08:43 ET Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain
Medical 21, Inc. has received regulatory approval in Spain to initiate its first-in-human clinical trial for the MAVERICS Coronary Revascularization Study. This study will evaluate the company's next-generation regenerative small-diameter coronary bypass graft, designed to improve coronary artery bypass grafting (CABG) procedures. The MAVERICS graft aims to provide a durable alternative to harvested vessels, enhancing patient outcomes. This approval marks a significant milestone for Medical 21 in advancing its mission to transform coronary bypass surgery.
Source: Longbridge
Medical 21, Inc. Announces Regulatory Approval to Initiate First-in-Human Clinical Study in Spain
Regulatory clearance enables launch of the MAVERICS Coronary Revascularization Study, advancing evaluation of the Company's next-generation synthetic small-diameter bypass graft.
Source: Morningstar
How the MAVERICS Graft Eliminates the Most Painful Part of Heart Bypass Surgery
Medical 21 replaces vessel harvesting, invasive leg surgery, and post-op complications with its small-diameter MAVERICS graft.